Teva Pharmaceutical Industries Limited (TEVA)

IL — Healthcare Sector
Peers: NTRA  BIIB  LH  STE  PODD  BNTX  DGX  GMAB  WAT  NBIX 

Automate Your Wheel Strategy on TEVA

With Tiblio's Option Bot, you can configure your own wheel strategy including TEVA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol TEVA
  • Rev/Share 14.4969
  • Book/Share 5.9582
  • PB 3.1923
  • Debt/Equity 2.5641
  • CurrentRatio 1.064
  • ROIC 0.0732

 

  • MktCap 21816579008.0
  • FreeCF/Share 0.8596
  • PFCF 22.1263
  • PE -138.0763
  • Debt/Assets 0.4366
  • DivYield 0
  • ROE -0.0258

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 3
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation TEVA Goldman -- Buy -- $24 June 6, 2025
Initiation TEVA Truist -- Buy -- $25 May 28, 2025
Upgrade TEVA JP Morgan Neutral Overweight -- $23 May 12, 2025

News

Completion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia Conducted by Teva Pharmaceuticals
TEVA
Published: February 10, 2025 by: Business Wire
Sentiment: Neutral

MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Paris:MEDCL): ACCESS HERE THE FULL PRESS RELEASE.

Read More
image for news Completion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia Conducted by Teva Pharmaceuticals

About Teva Pharmaceutical Industries Limited (TEVA)

  • IPO Date 1982-02-16
  • Website https://www.tevapharm.com
  • Industry Drug Manufacturers - Specialty & Generic
  • CEO Richard D. Francis
  • Employees 37000
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.